Combination of Trastuzumab and Tanespimycin (17-AAG, KOS-953) Is Safe and Active in Trastuzumab-Refractory HER-2–Overexpressing Breast Cancer: A Phase I Dose-Escalation Study von MODI, Shanu, STOPECK, Alison T, CROPP, Gillian F, JOHNSON, Robert G, HANNAH, Alison L, HUDIS, Clifford A, GORDON, Michael S, MENDELSON, David, SOLIT, David B, BAGATELL, Rochelle, WEINING MA, WHELER, Jennifer, ROSEN, Neal, NORTON, Larry

Volltext

Results of a Phase I Dose-escalating Study of the Antiangiogenic Agent, SU5416, in Patients with Advanced Malignancies von STOPECK, Alison, SHELDON, Marrae, VAHEDIAN, Mahmood, CROPP, Gillian, GOSALIA, Rishi, HANNAH, Alison

Volltext

Phase I dose escalation study of KOS-1584, a novel epothilone, in patients with advanced solid tumors von Lam, Elaine T., Goel, Sanjay, Schaaf, Larry J., Cropp, Gillian F., Hannah, Alison L., Zhou, Yiqing, McCracken, Barbara, Haley, Brandi I., Johnson, Robert G., Mani, Sridhar, Villalona-Calero, Miguel A.

Volltext

Dose-Finding and Pharmacokinetic Study of Cisplatin, Gemcitabine, and SU5416 in Patients With Solid Tumors von Kuenen, B. C.

Volltext

A phase 1 study of KOS-862 (Epothilone D) co-administered with carboplatin (Paraplatin®) in patients with advanced solid tumors von Monk, J. Paul, Villalona-Calero, Miguel, Larkin, Joe, Otterson, Greg, Spriggs, David S., Hannah, Alison L., Cropp, Gillian F., Johnson, Robert G., Hensley, Martee L.

Volltext

Phase I/pilot study of SU5416 (semaxinib) in combination with irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer von Lockhart, Albert Craig, Cropp, Gillian F, Berlin, Jordan D, Donnelly, Edwin, Schumaker, Robert D, Schaaf, Larry J, Hande, Kenneth R, Fleischer, Arthur C, Hannah, Alison L, Rothenberg, Mace L

Volltext

Phase I and Pharmacologic Study of the Tyrosine Kinase Inhibitor SU101 in Patients With Advanced Solid Tumors von ECKHARDT, S. G, RIZZO, J, THURMAN, A, SMITH, L, DRENGLER, R, ECKARDT, J. R, MOCZYGEMBA, J, HANNAH, A. L, VON HOFF, D. D, ROWINSKY, E. K, SWEENEY, K. R, CROPP, G, BAKER, S. D, KRAYNAK, M. A, KUHN, J. G, VILLALONA-CALERO, M. A, HAMMOND, L, WEISS, G

Volltext

Phase 1 First-in-Human Trial of the Vascular Disrupting Agent Plinabulin (NPI-2358) in Patients with Solid Tumors or Lymphomas von MITA, Monica M, SPEAR, Matthew A, PILAT, Maryjo, LLOYD, G. Kenneth, NEUTEBOOM, Saskia T. C, CROPP, Gillian, ASHTON, Edward, LORUSSO, Patricia M, YEE, Lorrin K, MITA, Alain C, HEATH, Elisabeth I, PAPADOPOULOS, Kyriakos P, FEDERICO, Kristine C, REICH, Steven D, ROMERO, Ofelia, MALBURG, Lisa

Volltext

Validation of liquid chromatography assay for the quantitation of ( Z)-3-[2,4-dimethyl-5-(2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-1H-pyrrol-3-yl]propionic acid (SU006668) in human... von Asad, Yasmin, Cropp, Gillian, Adams, Alison, O’Donnell, Anne, Raynaud, Florence, Judson, Ian, Workman, Paul

Volltext

Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in Patients with solid tumors von KUENEN, Bart C, ROSEN, Lee, PETERS, Godefridus J, CROPP, Gillian F, SCIGALLA, Paul, HOEKMAN, Klaus, PINEDO, Herbert M, GIACCONE, Giuseppe, SMIT, Egbert F, PARSON, Mandy R. N, LEVI, Marcel, RUIJTER, Rita, HUISMAN, Holger, KEDDE, Marc A, NOORDHUIS, Paul, VAN DER VIJGH, Wim J. F

Volltext

Phase I clinical, pharmacokinetic, and pharmacodynamic study of KOS-862 (Epothilone D) in patients with advanced solid tumors and lymphoma von Konner, Jason, Grisham, Rachel N., Park, Jae, O’Connor, Owen A., Cropp, Gillian, Johnson, Robert, Hannah, Alison L., Hensley, Martee L., Sabbatini, Paul, Miranov, Svetlana, Danishefsky, Samuel, Hyman, David, Spriggs, David R., Dupont, Jakob, Aghajanian, Carol

Volltext

Erratum to: Phase I clinical, pharmacokinetic, and pharmacodynamic study of KOS-862 (Epothilone D) in patients with advanced solid tumors and lymphoma von Konner, Jason, Grisham, Rachel N., Park, Jae, O’Connor, Owen A., Cropp, Gillian, Johnson, Robert, Hannah, Alison L., Hensley, Martee L., Sabbatini, Paul, Mironov, Svetlana, Danishefsky, Samuel, Hyman, David, Spriggs, David R., Dupont, Jakob, Aghajanian, Carol

Volltext

Phase 1 Clinical Trial of the Novel Structure Proteasome Inhibitor NPI-0052 in Patients with Relapsed and Relapsed/Refractory Multiple Myeloma (MM) von Richardson, Paul, Hofmeister, Craig, Jakubowiak, Andrzej, Zimmerman, Todd M., Spear, Matthew A., Palladino, Michael A., Longenecker, Angie M., Kelly, Susan L., Neuteboom, Saskia, Cropp, Gillian F, Lloyd, G. Kenneth, Hannah, Alison L., Anderson, Kenneth C.

Volltext

Clinical Trial of NPI-0052 (2nd generation proteasome inhibitor) in Patients Having Advanced Malignancies with Expanded RP2D Cohorts in Lymphoma and CLL von Price, Timothy, Padrik, Peeter, Townsend, Amanda, Mainwaring, Paul, Catley, Lawrence, Longenecker, Angie M., Cropp, Gillian, Palladino, Michael A., Lloyd, G. Kenneth, Spear, Matthew A., Millward, Michael

Volltext

First-in-Human Phase 1 Dose Escalation Study of NPI-0052, a Novel Proteasome Inhibitor, in Patients with Lymphoma and Solid Tumor von Hamlin, Paul A., Aghajanian, Carol, Hong, David, Younes, Anas, Palladino, Michael A., Longenecker, Angie M., Cropp, Gillian, Lloyd, G. Kenneth, Hannah, Alison L., Spear, Matthew A., Kurzrock, Razelle

Volltext

Abstract LB-202: Phase 1 dose escalation trial of the novel vascular disrupting agent NPI-2358 von Mita, Monica, Spear, Matthew A, Yee, Lorrin K, Papadopoulos, K P, Heath, Elisabeth, Romero, Ofelia, Lloyd, G Kenneth, Cropp, Gillian, Mita, Alain, LoRusso, Patricia

Volltext

Phase 1 Clinical Trial of NPI-0052, a Novel Proteasome Inhibitor in Patients with Multiple Myeloma von Richardson, Paul, Hofmeister, Craig C., Zimmerman, Todd M., Chanan-Khan, Asher Alban, Spear, Matthew A., Palladino, Michael A., Longenecker, Angie M., Cropp, Gillian, Lloyd, G. Kenneth, Wear, Sandra, Hannah, Alison L., Anderson, Kenneth C

Volltext

Phase 1 Clinical Trial of a Novel Proteasome Inhibitor (NPI-0052) in Patients with Lymphomas and Solid Tumors von Kurzrock, Razelle, Hamlin, Paul, Younes, Anas, Hong, David, Gordon, Michael, Spear, Matthew A., Palladino, Michael A., Lloyd, G. Kenneth, Longenecker, Angie M., Neuteboom, Saskia T.C., Cropp, Gillian F., Hannah, Alison, Aghajanian, Carol

Volltext

Pharmacokinetics and interspecies scaling of a novel VEGF receptor inhibitor, SU5416 von Sukbuntherng, Juthamas, Cropp, Gillian, Hannah, Alison, Wagner, Gregory S., Shawver, Laura K., Antonian, Lida

Volltext

Safety and Activity of KOS-953 in Patients with Relapsed Refractory Multiple Myeloma (MM): Interim Results of a Phase 1 Trial von Richardson, Paul G., Chanan-Khan, Asher A., Alsina, Melissa, Doss, Deborah, Landrigan, Beverly, Kettner, Dawn, Albitar, Maher, Mitsiades, Constantine, Cropp, Gillian F., Johnson, Robert G., Hannah, Alison L., Anderson, Kenneth C.

Volltext